Symptomatic and urodynamic responses in patients with reduced or no seminal emission during silodosin treatment for LUTS and BPH

Prostate Cancer and Prostatic Diseases

Volumn 14, Issue 2, 2011, Pages 143-148

  Roehrborn, C G ^a   Kaplan, S A ^b   Lepor, H ^c   Volinn, W ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d Clinical Research   (United States)

Author keywords

a blocker; BPH; IPSS score; LUTS; retrograde ejaculation

Indexed keywords

PLACEBO; SILODOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RETROGRADE EJACULATION; RISK ASSESSMENT; URINE FLOW RATE; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DOUBLE-BLIND METHOD; EJACULATION; HUMANS; INDOLES; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATISM; TREATMENT OUTCOME; URINATION DISORDERS; URODYNAMICS;

EID: 79956156019     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2010.46     Document Type: Article

References (19)

1. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol 2008; 15: 193-199 (Pubitemid 351316928)
2. Chapple CR. A comparison of varying alpha-blockers and other pharmacotherapy options for lower urinary tract symptoms. Rev Urol 2005; 7 (Suppl 4): S22-S30
3. American Urological Association Practice Guidelines Committee. Results of the Treatment Outcomes Analyses. In: Guideline on the management of benign prostatic hyperplasia (BPH). American Urological Association Education and Research, Inc., Chapter 3, 2006. Available at: http://www.auanet.org/content/ guidelines-and-quality-care/clinical-guidelines/main-reports/ bph-management/chapt-3-appendix.pdf
4. Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1-13 (Pubitemid 29265274)
5. Andersson KE, Gratzke C. Pharmacology of alpha1-adrenoceptor antagonists in the lower urinary tract and central nervous system. Nat Clin Pract Urol 2007; 4: 368-378 (Pubitemid 47307620)
6. Wilt TJ, Mac DR, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003; 1: CD002081
7. Lepor H. Long-term evaluation of tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Tamsulosin Investigator Group. Urology 1998; 51: 901-906 (Pubitemid 28240846)
8. Narayan P, Lepor H. Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology 2001; 57: 466-470 (Pubitemid 32192976)
9. Hellstrom WJ, Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006; 176: 1529-1533 (Pubitemid 44307193)
10. Michel MC. Alpha1-adrenoceptors and ejaculatory function. Br J Pharmacol 2007; 152: 289-290
11. Tatemichi S, Tomiyama Y, Maruyama I, Kobayashi S, Kobayashi K, Maezawa A et al. Uroselectivity in male dogs of silodosin (KMD-3213), a novel drug for the obstructive component of benign prostatic hyperplasia. Neurourol Urodyn 2006; 25: 792-799 (Pubitemid 44691386)
12. Yoshida M, Homma Y, Kawabe K. Silodosin, a novel selective alpha 1A-adrenoceptor selective antagonist for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs 2007; 16: 1955-1965 (Pubitemid 351403726)
13. Kobayashi S, Tomiyama Y, Tatemichi S, Hoyano Y, Kobayashi M, Yamazaki Y. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. Eur J Pharmacol 2009; 613: 135-140
14. Tatemichi S, Kobayashi K, Maezawa A, Kobayashi M, Yamazaki Y, Shibata N. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213)]. Yakugaku Zasshi 2006; 126 (Spec no): 209-216
15. Marks LS, Gittelman MC, Hill LA, Volinn W, Hoel G. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: Pooled results of 2 phase 3 studies. J Urol 2009; 181: 2634-2640
16. Kawabe K, Yoshida M, Homma Y. Silodosin, a new alpha1Aadrenoceptor- selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebocontrolled, double-blind study in Japanese men. BJU Int 2006; 98: 1019-1024 (Pubitemid 44536452)
17. Takao T, Tsujimura A, Kiuchi H, Matsuoka Y, Miyagawa Y, Nonomura N et al. Early efficacy of silodosin in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Int J Urol 2008; 15: 992-996
18. Kobayashi K, Masumori N, Hisasue S, Kato R, Hashimoto K, Itoh N et al. Inhibition of seminal emission is the main cause of anejaculation induced by a new highly selective alpha1Ablocker in normal volunteers. J Sex Med 2008; 5: 2185-2190
19. Barry MJ, Williford WO, Chang Y, Machi M, Jones KM, Walker- Corkery E et al. Benign prostatic hyperplasia specific health status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients? J Urol 1995; 154: 1770-1774